Sunresin New Materials Co (300487) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
28 Oct, 2026Executive summary
Q3 revenue rose 16.39% YoY to ¥798.4m and attributable net income increased 9.12% to ¥226.1m; YTD revenue grew 12.57%, while attributable net income edged down 0.78%.
YTD operating cash flow increased 26.77% to ¥683.1m, supporting liquidity despite substantial FX-related financial costs.
Financial highlights
YTD revenue was ¥2,176.5m versus ¥1,933.4m in the prior-year period; Q3 revenue was ¥798.4m, up 16.39% YoY.
YTD attributable net income was ¥646.6m, down 0.78%; Q3 attributable net income was ¥226.1m, up 9.12% YoY.
YTD adjusted attributable net income, excluding non-recurring items, was ¥639.0m, down 0.04%; Q3 adjusted net income was ¥225.4m, up 11.05%.
Total assets reached ¥7,167.3m at quarter-end, up 8.66% from year-end; parent-attributable equity was ¥4,890.9m, up 11.42%.
Key financial ratios and metrics
YTD basic EPS was ¥1.27, down 1.55% YoY; Q3 basic EPS was ¥0.45, up 9.76%.
YTD weighted average ROE was 13.75%, down 1.96 percentage points YoY.
YTD operating cash flow was ¥683.1m, up 26.77% YoY, compared with ¥538.8m in the prior-year period.
Latest events from Sunresin New Materials Co
- Revenue up 10.47% YoY, adjusted net profit up 18%, life sciences segment leads growth.300487
Q2 2026 - Record revenue and profit, robust segment growth, and strong international expansion.300487
Q2 2024 - Record revenue and profit, strong core growth, and overseas sales up 45.1% year-over-year.300487
Q4 2024 - Revenue and net profit rose double digits year-over-year, with robust cash flow and expansion.300487
Q3 2024 - Net profit rose 10% to ¥444.5 million on improved margins and strong cash flow.300487
Q2 2025 - Net profit up 14.18% year-over-year despite 8.58% revenue drop; cash flow surged.300487
Q1 2025 - Record revenue and profit growth driven by core segments and robust R&D investment.300487
Q4 2025 - Q3 saw double-digit revenue growth and new investment in a life sciences materials park.300487
Q3 2025 - Revenue up 5.24%, net profit down 5.81%, and operating cash flow up 36.59% year-over-year.300487
Q1 2026